Results 201 to 210 of about 61,821 (357)

Landscape of T-cell engagers in solid tumors. [PDF]

Oncologist
Garcia-Lorenzo E, Dorta M, Doger B, Pedregal M, Moreno V.   +4 more
europepmc   +1 more source

Incidence and Survival of Hemophagocytic Lymphohistiocytosis Over Two Decades: A Population‐Based Study

European Journal of Haematology, EarlyView.
ABSTRACT Adult hemophagocytic lymphohistiocytosis (HLH) is a rare, life‐threatening syndrome triggered by various conditions. A nationwide study of the incidence and outcomes of HLH in Denmark over 23 years (2000–2023) was performed. Adults (≥ 18 years) with HLH and triggering diseases were identified in the Danish National Patient Registry and/or the ...
Mads Okkels Birk Lorenzen, Martin Jensen, Rasmus Rask Kragh Jørgensen, Paw Jensen, Henrik Frederiksen, Dennis L. Hansen, Daniel El Fassi, Morten Nørgaard Andersen, Tarec Christoffer El‐Galaly   +8 more
wiley   +1 more source

Ivonescimab combined with chemotherapy for the treatment of metastatic cervical cancer: A case report and literature review. [PDF]

Hum Vaccin Immunother
Xu M, Qiu S, Zhou J, Zhang Y.
europepmc   +1 more source

Figure S8 from A Novel Designed Anti–PD-L1/OX40 Bispecific Antibody Augments Both Peripheral and Tumor-Associated Immune Responses for Boosting Antitumor Immunity

Baocun Li, Shiyong Gong, Nianying Zhang, Beilei Shi, Zhou Lv, Yu Zhang, Naren Gaowa, Liqin Dong, Danqing Wu, Jianfu Wu, Fan Liu, Rui Zhang, Ramin Behzadigohar, Vinod Ganju, Chengbin Wu, Xuan Wu   +15 more
openalex   +1 more source

Loncastuximab Tesirine in Relapsed/Refractory Diffuse Large B‐Cell Lymphoma: Evidence and Practical Guidance From Italian Clinical Experience

European Journal of Haematology, EarlyView.
ABSTRACT Patients with relapsed/refractory (R/R) diffuse large B‐cell lymphoma (DLBCL) who progress to the third‐line setting face a lack of standardized treatment, despite the presence of multiple available therapies. In this context, antibody–drug conjugates represent a relatively new class of anticancer agents; among them, loncastuximab tesirine is ...
Francesca Bonello, Andrea Aroldi, Alessia Castellino, Lara Mannelli, Elia Boccellato, Serena Rosati, Luisa Verga, Umberto Vitolo   +7 more
wiley   +1 more source

A potent Gc neutralizing antibody reveals architecture-dependent bispecific protection against SFTSV. [PDF]

Emerg Microbes Infect
Lu H, Li L, Zhang N, Liu Y, Liu B, Sun Y, Zhang J, Liu S, Luo J, Liao J, Lv K, Yue X, Xu M, Zhao J, Wu X, Chen X, Tao C, Guo Y, Zhang Z, Wang M, Chen YQ.   +20 more
europepmc   +1 more source

Preparation of a Bispecific Antibody to Ovomucoid and Horseradish Peroxidase by Chemical Recombination Method.

, 1999
Sakiko Miyakoshi, Hiroshi Shinmoto, Masuko Kobori, Masami Yonekura, Tojiro Tsushida   +4 more
openalex   +2 more sources

Prognostic Impact of Chromosome 1q Gain/Amplification in Multiple Myeloma Treated With Daratumumab‐Based Regimens

European Journal of Haematology, EarlyView.
ABSTRACT Gain/amplification of chromosome arm 1q (+1q) is among the most frequent cytogenetic abnormalities (CAs) in multiple myeloma (MM), and a recognized marker of poor prognosis, now integrated into modern risk stratification systems. The advent of anti‐CD38 monoclonal antibodies, particularly daratumumab, has significantly improved outcomes ...
Emiliano Barbieri, Laura Arletti, Micol Quaresima, Elena Rivolti, Luca Braglia, Cecilia Fabiano, Adriana Maria Rita Alfano, Monia Rinaldini, Veronica Bizzarri, Chiara Cattani, Maria Marinelli, Barbara Gamberi   +11 more
wiley   +1 more source

Advances in multiple myeloma: key updates from the ASH 2025 meeting. [PDF]

J Hematol Oncol
Naing PT, Baljevic M.
europepmc   +1 more source

298 Therapeutic potential of IMPT-601, a Claudin18.2/TGF-β bispecific CAR, against gastric cancer [PDF]

Melanie L. Munguia, Jessica Reyes, Orit Foord, Ethan BenDavid, Jiajia Cui   +4 more
openalex   +1 more source